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INTRODUCTION
I
N MAMMALS, HEMATOPOIESIS shifts to the bone marrow in
late embryogenesis, coincident with the appearance of a
marrow cavity.
(1) There hematopoiesis is sustained
throughout adult life unless forced out of the bone marrow
into extramedullary sites by pathological conditions. All
hematopoietic lineages arise from the hematopoietic stem
cell (HSC), and maintenance of HSC self-renewal and
differentiation are critically dependent on the presence of a
supportive microenvironment, or niche. The existence of
such a niche within the bone marrow was ﬁrst postulated by
Schoﬁeld,
(2) and the vital role of the bone marrow micro-
environment has been convincingly shown in the three
decades since.
The marrow microenvironment is comprised of cells of
multiple lineages, including ﬁbroblast-like cells, adipo-
cytes, osteoblasts, and endothelial cells. Recent studies
have begun to highlight the contributions of individual
lineages to the hematopoietic niche, with the greatest
weight of evidence thus far in support of important roles
for osteoblasts and the vasculature.
(3–5) In humans,
CD146
+subendothelial cellshave beenreportedto serve as
skeletal progenitors capable of generating cells that orga-
nize a hematopoietic microenvironment on transplanta-
tion.
(6) Subsequent studies have shown that the endosteal
surface is rich in vasculature with close approximation of
osteoblasts and vessel walls.
(7,8) In trabecular bone, it is
unlikely that there are physically distinct endosteal and
perivascular/vascular niches, although the functional roles
of osteoblasts and vascular cells may well differ. This re-
view will focus speciﬁcally on the role of cells of the oste-
oblast lineage within the bone marrow niche. In particular,
we will examine the contribution of osteoblasts in sup-
porting hematopoietic stem cells and contrast this with how
distinct stages of osteoblast precursors support developing
B lymphocytes, one of the best-characterized speciﬁc he-
matopoietic lineages.
OSTEOBLASTS ARE A DIVERSE POPULATION
To date in the HSC microenvironment literature, oste-
oblasts have largely been considered as a uniform entity.
However, within the osteoblast lineage, there are multiple
stages, just as there are intermediates between HSCs and
mature B lymphocytes. The osteoblast lineage is derived
from a putative mesenchymal stem cell, whose location and
identity in vivo has yet to be ﬁrmly established. Once
committed to the osteoblast lineage, through a process that
requires the expression of Runx2, cells differentiate and
express progressively more mature markers of osteo-
blastogenesis including osterix, alkaline phosphatase, and
collagen type I.
(9) Mature osteoblasts are identiﬁed by their
cuboidal morphology and localization to the bone surface
(endosteal or periosteal), where they secrete extracellular
matrix and express markers of terminal differentiation
such as osteocalcin. Terminally differentiated osteoblasts
themselves have one of three known fates—to become
quiescent lining cells, to differentiate further into osteo-
cytes surrounded by mineral matrix, or to die by apopto-
sis.
(10) Whereas osteocytes and mature osteoblasts are
easily identiﬁable in histological sections, little is known
about the location and fate of osteoprogenitors in vivo.
Osteoblast precursors are likely located in the marrow
space, because bone marrow ﬂushed from the diaphysis
contains cells capable of adhering to plastic, and, when
cultured under osteogenic conditions, a fraction of this
adherent population is capable of differentiating into cells
that express markers of osteoblasts and mineralize the
surrounding matrix.
(9) In certain disease states such as se-
vere hyperparathyroidism
(11) or ﬁbrous dysplasia,
(12) the
hematopoietic marrow is replaced by ﬁbroblastoid stromal
cells that express markers of the osteoblast lineage.
(13,14)
Detailed characterization of osteoprogenitors thus far has
been limited by a lack of cell surface markers that would
allow prospective identiﬁcation and isolation of deﬁned
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759precursor populations. However, more recently, the de-
velopment of ﬂuorescent reporter mice in which variants of
green ﬂuorescent protein (GFP) are driven by osteoblast
stage-speciﬁc promoters has revolutionized our ability to
study osteoblast differentiation in vivo.
(15,16) That each
stage of osteoblast differentiation is functionally distinct is
underscored by the ﬁnding, for example, that, whereas dele-
tion of b-catenin in osteoprogenitors inhibits osteoblast dif-
ferentiation in favor of a chondrocytic fate,
(17–19) deletion in
differentiated osteoblasts results in severe osteopenia largely




suggested by anatomic evidence. Several groups reported
that primitive hematopoietic cells seem to be enriched near
the endosteal surface,
(22,23) whereas more differentiated
progenitors are localized more centrally within the bone
marrow space.
(24,25) More recently, visualization of labeled
hematopoietic stem/progenitor cells (HSPCs) by intravital
microscopy showed that HSPCs localized adjacent to en-
dosteal osteoblasts in the settings of HSPC engraftment or
expansion; more mature progenitors were positioned fur-
ther from osteoblasts.
(7,8) Moreover, the migration of he-
matopoiesis from the fetal liver to the bone marrow during
embryonic development is critically dependent on normal
boneformationandturnover.MicedeﬁcientinRunx2failto
develop a mineralized skeleton,
(26,27) and, in these mice,
hematopoiesis shifts to extramedullary organs.
(28) In con-
trast, mice lacking macrophage colony-stimulating factor
(M-CSF) have defective osteoclasts and therefore osteope-
trosis and also develop extramedullary hematopoiesis.
(29)
In vitro, hematopoietic cell differentiation requires the
supporting presence of stromal cells,
(30) a task that can be
performed by cells of the osteoblast lineage.
(31,32) A func-
tional role for osteoblasts in regulating hematopoiesis in
vivowas shown bytargeted ablation ofosteoblasts, through
gancyclovir treatment of mice expressing herpes simplex
thymidinekinase only in differentiated osteoblasts.
(33) Loss
of osteoblasts led to a dramatic reduction of bone marrow
cellularity and resultant extramedullary hematopoiesis,
consistent with the loss of the ability of the bone to support
hematopoiesis.
(34) Ablation of osteoblasts was followed
acutelybylossofB-celllymphopoiesisanderythropoiesisinthe
bone marrow, with a later decline in primitive hematopoietic
cells.
(34,35) Additionally, cells of the osteoblast lineage seem to
play an active role in HSC mobilization, for instance in re-
sponse to granulocyte-colony stimulating factor (G-CSF),
(36,37)
although their precise role is still being determined.
Genetic manipulation of either the PTH/PTH-related
peptide receptor (PPR) in osteoblasts
(38) or the BMPR1a
receptor
(39) leads to increased osteoblast number and en-
hanced HSC frequency. However, osteoblast number is not
the sole determinant of the number of HSCs, because the
reduced osteoblast number seen in biglycan knockout
(KO) mice is not associated with a decrease in HSCs or any
other hematopoietic defect.
(40) Several factors elaborated
or inﬂuenced by osteoblasts have been identiﬁed that can







(46) Notch signaling has been implicated by
the ﬁnding that increased expression of the Notch ligand
Jagged-1 (Jag1) in osteoblasts after PPR activation is asso-
ciated with an increase in HSC number and that this in-
crease in HSCs could be blocked by administration of a
g-secretaseinhibitor,
(38) although Mx1-Cre-mediated deletion
of Jag1 in the microenvironment has been reported to yield no
phenotype.
(47) Some studies have suggested the importance
of N-cadherin,
(8,39,48) whereas others have disputed the rel-
evance of N-cadherin.
(40) Thus, whereas osteoblasts clearly
have a role in the establishment of an HSC niche, the mo-
lecular mechanisms remain incompletely deﬁned, and there
are many unanswered questions. In particular, a require-
ment for direct contact between HSCs and osteoblasts, as
opposed to proximity to diffusible factors, has yet to be
deﬁnitively shown in vivo, and the precise characterization
of the osteoblasts capable of supporting HSCs is very in-
complete. Furthermore, the interplay between cells of the
osteoblast lineage and perivascular/vascular cells in the
bone marrow niche are largely unknown. In the future, cell-
speciﬁc ablation of candidate factors will be useful in clari-
fying many of these issues.
DISTINCT NICHES EXIST WITHIN THE BONE
MARROW FOR DEVELOPING B CELLS
Within the bone marrow, speciﬁc niches have also been
identiﬁed for maturing hematopoietic cells, including
platelets
(49) and B lymphocytes. B-lymphocyte develop-
ment is well characterized, and several studies now point to
the existence of distinct niches for each stage of differen-
tiation. B lymphocytes are generated from HSCs through a
common lymphoid progenitor (CLP), and within the bone
marrow, the earliest identiﬁable B-cell precursor is the
prepro-B cell. Prepro-B cells differentiate into pro-B cells,
which in turn gives rise to pre-B cells.
(50) Immature IgM
+ B
cells migrate into the periphery, where maturation occurs
in the spleen. Tokoyoda et al.
(51) found that, within bone
marrow stroma, CXCL12 and interleukin (IL)-7, two fac-
tors with critical roles at differing stages of B lymphopoi-
esis, are expressed by separate stromal cell populations.
Whereas prepro-B cells are in contact with CXCL12-
expressing stromal cells, more differentiated pro-B cells
instead are found in contact with IL-7–expressing cells,
suggesting that as B-cell precursors differentiate, they mi-
grate among discrete populations of stromal cells. Finally,
pre-B cells do not contact either CXCL12- or IL-7–ex-
pressing cells, consistent with the ﬁnding that in vitro pre-B
cells are no longer dependent on stromal cell support. In-
triguingly, end-stage plasma cells return to the bone mar-
row, where dendritic cells provide a supportive niche,
(52)
further supporting the possibility that each stage of B-
lymphocyte differentiation may rely on a speciﬁc niche.
GSa MEDIATES OSTEOBLASTIC REGULATION
OF B-CELL DEVELOPMENT
In addition to hematopoietic progenitors, the bone mar-
row contains stromal cells that include precursors of the
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bycellsoftheosteoblastlineage,andbothareupregulatedin
response to PPR-mediated signaling.
(35,38,53) This raises the
possibility that either or both populations of stromal cells
expressing CXCL12 or IL-7 may share characteristics with
cells of the osteoblast lineage. Consistent with this model,
Zhu et al.
(35) found that primary calvarial cells, which in-
clude osteoblasts and their progenitors, are capable of sup-
porting B lymphopoiesis in culture, and that this supportive
ability is enhanced by treatment with PTH.
The PPR is a G protein–coupled receptor (GPCR), and
the heterotrimeric G protein subunit Gsa is a major
downstream mediator of PPR signaling through the pro-
tein kinase A pathway.
(54) We have deleted Gsa in early
osteoprogenitors using Cre recombinase driven by osterix,
a transcription factor expressedearly inosteoblastogenesis.
Gsa
OsxKO mice have a dramatic reduction in trabecular
bone.
(55) Because enhanced signaling through PPR is as-
sociated with increased HSC number,
(38) and because PTH
can also stimulate osteoblastic support of B-lymphocyte
differentiation,
(35) we asked whether loss of Gsa would
conversely have a negative impact on hematopoiesis. In
fact, Gsa
OsxKO mice have a signiﬁcant decrease in B-cell
precursors in the bone marrow, and this results in a re-
duction in circulating B lymphocytes.
(55) Within the bone
marrow, B lymphopoiesis is impaired at the pro-B to pre-B
cell transition, whereas earlier prepro-B cells are unaf-
fected. Consistent with the ﬁnding that prepro-B cells are
associated with CXCL12
+ cells, CXCL12 expression is not
reduced in Gsa
OsxKO osteoblasts. In contrast, IL-7 mRNA
is signiﬁcantly decreased, and the reduction in pro-B and
pre-B cells is similar to that found in mice lacking either IL-
7 or the IL-7 receptor.
(56,57) Moreover, exogenous IL-7 is
sufﬁcient to rescue the pro-B deﬁcit in Gsa
OsxKO mice. The
B-lymphocyte deﬁciency can be rescued by transplanting
KO bone marrow into a wildtype host, conﬁrming that this
is caused by a defect in the microenvironment. Thus, Gsa
signaling within cells of the osteoblast lineage is required
for normal bone marrow B lymphopoiesis and likely in-
volves IL-7 production. Candidate Gsa-coupled GPCRs in
the osteoblast lineage that might regulate B-lymphocyte
development include PPR and the prostaglandin E2 re-
ceptors EP2R and EP4R.
(58) Of note, prostaglandin E2 has
also been reported to modulate the HSC niche.
(59)
MODEL FOR OSTEOBLASTIC SUPPORT OF
HEMATOPOIETIC DEVELOPMENT
To summarize, within the bone marrow, cells of the os-
teoblast lineage have unequivocally been shown to con-
stitute a niche for HSCs and now have been found to
support differentiation of the B-lymphocyte lineage as
well. Ablation of Gsa early in the osteoblast lineage results
in loss of pro-B cells and is associated with decreased ex-





(51) perhaps IL-7–expressing stromal
cells represent a subset of cells of the osteoblast lineage in-
volved in supporting hematopoiesis.
Based on the evidence to date regarding the role of os-
teoblast lineage cells in the bone marrow niche, we propose
that cells derived from osteoprogenitors and in various
stages of differentiation provide distinct niches for hema-
topoietic cells. Thus, as others have postulated,
(3–5,60) ter-
minally differentiated osteoblasts along the endosteal sur-
face would serve as a niche for HSCs, perhaps in their most
quiescent stage.
(61) Once committed to the B-cell lineage,
prepro-B cells migrate to CXCL12
+ cells. Differentiation
into pro-B cells requires IL-7, produced by osteoblast lin-
eage cells expressing osterix. Thus, the earliest hemato-
poietic progenitor, the HSC, is supported by mature oste-
oblasts, whereas more differentiated pro-B cells are
themselves supported by osteoprogenitors located in the
marrow space (Fig. 1). In support of the concept that ma-
ture osteoblasts and stromal osteoprogenitors have differ-
ential effects on hematopoietic cells, Balduino et al.
(62)
found that both osteoblasts and subendosteal reticular cells
express osteogenic markers. However, whereas osteoblasts
maintain hematopoietic progenitors with low proliferation,
the stromal reticular cell fraction, which likely includes
osteoprogenitors, induces proliferation and differentiation
of hematopoietic cells. One prediction of this model is that
CXCL12(hi)-reticular cells,
(60) which contact intermediary
prepro-B cells, might also represent a subset of the osteo-
blast lineage. IL-7
+Osx
+ cells and CXCL12(hi) cells may or
may not be the same population as those Osx
+ cells that
ultimately give rise to terminally differentiated osteoblasts.
Much work remains to be done to conﬁrm such a model,
but it provides a framework with which to begin to dissect
the mechanisms of cross-talk between the skeletal and
hematopoietic systems. In addition, whether cells of the
osteoblast lineage play any role in supporting hematopoi-
etic lineages other than B lymphocytes is still unknown.
CLINICAL RELEVANCE
Theroleofthe microenvironment indisease pathogenesis
is garnering increasing attention, with several recent reports
highlighting the importance of the microenvironment on
neoplasia.
(63–66) It has long been known clinically that many
malignancies display a predilection for metastasis to bone,
and whether these predilections involve the same molecular
mechanisms as niche interactions is an area of intense in-
terest. With respect to B-cell lineage malignancies, multiple
myeloma bone disease is a devastating complication that
involves interactions between malignant plasma cells, oste-
oblasts, and osteoclasts.
(67) In a model of human MLL-AF9
leukemia, myeloid versus lymphoid lineage could be di-
rected by changes in the microenvironment.
(68) How mye-
loid malignancies are inﬂuenced by osteoblasts is at present
unknown. However, human leukemic cells transplantedinto
NOD/SCID mice home to osteoblasts,
(69,70) strongly sup-
porting a functional relationship and suggesting that inter-
vening in such an interaction may be a worthy area of study.
CONCLUDING REMARKS
Because of the very nature of the bone marrow niche, at
the intersection of hematopoietic, skeletal, and vascular
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the diverse origins ofthe investigators.Aswemoveforward,
there will be a need to reconcile anatomic, genetic, and
functional data to better delineate the relative contributions
and roles of the myriad components. For example, HSCs
have been variably identiﬁed by immunophenotype, im-
munohistochemical localization, and functional studies.
HSCs themselves may also exert some inﬂuence on the
microenvironment, because HSCs have been shown to exert
stimulatory effects on osteogenic differentiation of bone
marrow stromal cells in a co-culture system.
(71) In addition,
bone-resorbing osteoclasts, derived from the macrophage/
monocyte lineage,
(72)have been implicated inthe regulation
of the HSC niche,
(73) highlighting the complexity of cross-
talk between an ever-growing list of participants. On the
stromal side, a variety of promoters have been used to dis-
sect the microenvironment, and a better understanding of
the spatial and temporal relationships between markers
expressed by these cell populations is needed. As an ex-
ample, Mx1-Cre is commonly used in combination with re-
ciprocal transplantation studies to elucidate the relative in-
trinsic versus extrinsic contributions of various gene
mutations to hematopoietic phenotypes. However, the ex-
pression of Mx1-Cre within the stromal microenvironment
and its relative efﬁcacy in different stromal cell compart-
ments remains obscure. In particular, although Mx1 is ex-
pressed in the skeleton,
(74) phenotypes resulting from Mx1-
Cre–mediated deletion differ from those obtained with os-
teoblast-speciﬁc promoter-driven Cre recombinases. Dele-
tion of Rb in the microenvironment with Mx1 leads to
myeloproliferative disease,
(63) whereas deletion of Rb
within the osteoblast lineage results in enhanced predilec-
tion for development of osteosarcoma.
(75)
In summary, osteoblasts cannot be considered as a uni-
form entity, but rather as a complex population of cells
with a broad spectrum of developmental potential. A bet-
ter understanding of how anatomic localization, immuno-
phenotype, and stage of differentiation and cellular func-
tion are interrelated will be crucial to advance the biology
of osteoblasts within the bone marrow niche.
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